What question did this study set out to answer?

To assess the efficacy and safety of HS-20137 for treating moderate-to-severe plaque psoriasis.

March 25, 2026Dermatology and Therapy0 citationsOpen Access

HS-20137 for Chinese Moderate-to-Severe Psoriasis: A Randomized, Double-Blinded, Phase 2 Study

LCLin CaiPeking University XWXiaohua WangQinghai Normal University LZLitao ZhangTianjin University of Traditional Chinese Medicine

Key Points

To assess the efficacy and safety of HS-20137 for treating moderate-to-severe plaque psoriasis.
Randomized, double-blinded study design
Involved patients with moderate-to-severe plaque psoriasis
Evaluated both efficacy and safety of the treatment in a larger cohort over an extended period.
HS-20137 demonstrated significant efficacy in reducing psoriasis severity.
Safety assessments indicated manageable side effects.
Results suggest HS-20137 could be a promising treatment option for patients with moderate-to-severe psoriasis.

Abstract

Introduction: HS-20137 is a novel interleukin-23 inhibitor and is suggested to be effective for the treatment of psoriasis in a phase 1b study. Our study aimed to evaluate the effcacy and safety of HS-20137 in patients with moderate-to-severe plaque psoriasis in a larger and longer phase 2 study.

AI से पूछें

Bookmark

View Full Paper